These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2029579)

  • 1. Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa.
    Austin RC; Rachubinski RA; Ofosu FA; Blajchman MA
    Blood; 1991 May; 77(10):2185-9. PubMed ID: 2029579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression in a cell-free system of normal and variant forms of human antithrombin III. Ability to bind heparin and react with alpha-thrombin.
    Austin RC; Rachubinski RA; Fernandez-Rachubinski F; Blajchman MA
    Blood; 1990 Oct; 76(8):1521-9. PubMed ID: 2207328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity.
    Devraj-Kizuk R; Chui DH; Prochownik EV; Carter CJ; Ofosu FA; Blajchman MA
    Blood; 1988 Nov; 72(5):1518-23. PubMed ID: 3179438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin.
    Ireland H; Lane DA; Thompson E; Walker ID; Blench I; Morris HR; Freyssinet JM; Grunebaum L; Olds R; Thein SL
    Br J Haematol; 1991 Sep; 79(1):70-4. PubMed ID: 1911389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
    Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
    Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding.
    Tripodi A; Krachmalnicoff A; Mannucci PM
    Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissociation of heparin-dependent thrombin and factor Xa inhibitory activities of antithrombin-III by mutations in the reactive site.
    Theunissen HJ; Dijkema R; Grootenhuis PD; Swinkels JC; de Poorter TL; Carati P; Visser A
    J Biol Chem; 1993 Apr; 268(12):9035-40. PubMed ID: 8473344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with, but not cleavage by, alpha-thrombin.
    Austin RC; Sheffield WP; Rachubinski RA; Blajchman MA
    Biochem J; 1992 Mar; 282 ( Pt 2)(Pt 2):345-51. PubMed ID: 1546950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").
    Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE
    J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombin III Avranches, a new variant with defective serine-protease inhibition--comparison with antithrombin III Charleville.
    Aiach M; Roncato M; Chadeuf G; Dezellus P; Capron L; Fiessinger JN
    Thromb Haemost; 1988 Aug; 60(1):94-6. PubMed ID: 3187951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homozygous variant of antithrombin III: AT III Fontainebleau.
    Boyer C; Wolf M; Vedrenne J; Meyer D; Larrieu MJ
    Thromb Haemost; 1986 Aug; 56(1):18-22. PubMed ID: 3775688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms responsible for catalysis of the inhibition of factor Xa or thrombin by antithrombin using a covalent antithrombin-heparin complex.
    Paredes N; Wang A; Berry LR; Smith LJ; Stafford AR; Weitz JI; Chan AK
    J Biol Chem; 2003 Jun; 278(26):23398-409. PubMed ID: 12695507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization of an antithrombin exosite that promotes rapid inhibition of factors Xa and IXa dependent on heparin activation of the serpin.
    Izaguirre G; Zhang W; Swanson R; Bedsted T; Olson ST
    J Biol Chem; 2003 Dec; 278(51):51433-40. PubMed ID: 14532267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis.
    Okajima K; Abe H; Maeda S; Motomura M; Tsujihata M; Nagataki S; Okabe H; Takatsuki K
    Blood; 1993 Mar; 81(5):1300-5. PubMed ID: 8443391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification and further characterization of antithrombin III Milano: lack of reactivity with thrombin.
    Wolf M; Boyer-Neumann C; Meyer D; Tripodi A; Mannucci PM; Larrieu MJ
    Thromb Haemost; 1987 Oct; 58(3):888-92. PubMed ID: 3433251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-directed mutagenesis of alanine-382 of human antithrombin III.
    Austin RC; Rachubinski RA; Blajchman MA
    FEBS Lett; 1991 Mar; 280(2):254-8. PubMed ID: 2013320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin family.
    Olds RJ; Lane DA; Caso R; Panico M; Morris HR; Sas G; Dawes J; Thein SL
    Blood; 1992 Mar; 79(5):1206-12. PubMed ID: 1536946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the COOH-terminal region of antithrombin III. Evidence that the COOH-terminal region of the inhibitor enhances the reactivity of thrombin and factor Xa with the inhibitor.
    Nishioka J; Suzuki K
    J Biol Chem; 1992 Nov; 267(31):22224-9. PubMed ID: 1331047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residues Tyr253 and Glu255 in strand 3 of beta-sheet C of antithrombin are key determinants of an exosite made accessible by heparin activation to promote rapid inhibition of factors Xa and IXa.
    Izaguirre G; Olson ST
    J Biol Chem; 2006 May; 281(19):13424-13432. PubMed ID: 16517611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.